Expanded Access Policy

Expanded Access Policy

Daelion Therapeutics is a clinical-stage pharmaceutical company. We are committed to developing novel therapeutics that promote cancer immunity.

At this time, Daelion does not offer an expanded access program and is not accepting single patient expanded access requests for its investigational products. Our current focus is on completing development programs to obtain the necessary safety and efficacy data for regulatory approval as quickly and as safely as possible. As our investigational product (odetiglucan) advances in development, we will review our expanded access policy and may make updates to it.

Information about our clinical trials, including eligibility criteria and locations, is available at www.clinicaltrials.gov and on the Daelion website daeliontherapeutics.com. Questions about Daelion’s investigational products and clinical trials may be addressed to skarel@daeliontherapeutics.com.